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Abstract Some of the important properties of probiotics are
the ability to survive during gastrointestinal transit and to
modulate the immune functions. The objectives of the
reported study were to assess in vivo gastrointestinal sur-
vival of orally administered Pediococcus pentosaceus OZF
using an animal model BALB/c mice, and to examine its
effects on the immune response. Following oral administra-
tion to mice, the ability of Pediococcus pentosaceus OZF to
pass and survive through the mouse gastrointestinal system
was investigated by analyzing the recovery of the strain in
fecal samples. Microbiological and polymerase chain reac-
tion (PCR) methods proved that the strain OZF could over-
come specific conditions in the gastrointestinal tract of mice
and reach the intestine alive after ingestion. To observe the
effect of oral administration on immune response, IL-6,
IL-12 and IFN-γ were measured by ELISA, and the strain
OZF was found to cause increases in IL-6 synthesis in
regularly fed mice. However, stimulation was carried out
with various concentrations of bacterial ssDNA and heat
killed cells of Pediococcus pentosaceus OZF. The heat
killed cells of the strain OZF were shown to produce IFN-
γ independently from IL-12. On the other hand, a signifi-
cant difference between control and experimental group was
noticed when lipopolysaccharide, a TLR4 (toll like receptor)
ligand, was used. Overall, Pediococcus pentosaceus OZF
may be a valuable probiotic strain for therapeutic uses.
Nevertheless, further studies on the mechanisms of immu-
nomodulatory effect will allow for better clarification of the
immune functions of this strain.
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Introduction
Lactic acid bacteria (LAB) are very important in the pro-
duction of many fermented foods (cheese, yogurt, etc.).
Applications of these organisms are now being extended to
the area of health improvement, which is known as a pro-
biotic activity. An expert committee defined the term pro-
biotic, popularized by Roy Fuller in 1989, as “living
microorganisms, which upon ingestion in certain numbers
exert health benefits to the host animal by improving its
intestinal microbial balance” (Guarner and Schaafsma
1998). Several aspects, including general, functional and
technological characteristics, have to be taken into consid-
eration in the selection process of probiotic strains. The
criteria for selecting a good probiotic strain have been listed
comprehensively by several authors (Collins et al. 1998;
Salminen et al. 1998; Deshpande et al. 2011). A successful
probiotic needs to be able to reach the distal part of the
intestine successfully in order to have a beneficial effect
(Freter 1992; Havenaar et al. 1992; Lo Curto et al. 2011).
In order to survive in and colonize the gastrointestinal tract
(GIT), ingested bacteria need to express high tolerance to
the enzymes in the oral cavity (e.g., lysozyme), as well as to
the digestion process in the stomach (e.g., exposure to low
pH) and the intestine (e.g., exposure to bile); to have the
ability for adhesion to the intestinal surfaces. However, it is
reported that many bacteria cannot tolerate these stresses
(Fujiwara et al. 2001; Suskovic et al. 2001; Iannitti and
Palmieri 2010).
In recent years, the incorporation of probiotic bacteria into
foods has received increasing scientific interest for health
promotion and disease prevention such as anti-infection prop-
erties (Isolauri et al. 1991), beneficial effects in intestinal
inflammation (Peran et al. 2005), immunomodulatory activity
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(Olivares et al. 2006), and efficacy in the prevention of allergic
diseases (Furrie 2005). Our immune system is one of the most
dynamic body components in determining our state of health
or disease. Therefore, the immunoregulatory effects of LAB
are of primary interest and nowadays there is growing interest
in research of immunobiotic LAB that have an ability to
modulate or stimulate the gastrointestinal immune system
(Nagao et al. 2000; Sheih et al. 2001; Lomax and Calder
2009). Many researchers actively studied the immunomodu-
latory function of LAB, reporting selected strains as able to
prevent or reduce allergies and to preserve the host from
various infectious diseases and cancer (Yasui et al. 1999;
Takagi et al. 2001; Shida et al. 2002; Repa et al. 2003;
Fujiwara et al. 2004; Kimoto et al. 2004). Several studies in
the literature focused on the ability of selected probiotics to
modulate in vitro cytokine production by human or murine
cells (Niers et al. 2005; Baken et al. 2006; Helwig et al. 2006;
Shida et al. 2006; Perez-Cano et al. 2010). These effects range
from stimulation to inhibition of several pro-inflammatory and
anti-inflammatory cytokines, as well as some chemokines,
and these effects are often strain-specific and each strain
appears to have its own unique immunomodulatory profile
(Niers et al. 2007). The pro-inflammatory cytokines secreted
by the epithelium, such as tumor necrosis factor (TNF)-α,
interleukin (IL)-1, IL-6, IL-8 and IL-12, are hallmarks of the
inflammatory responses in the intestine (Isolauri 1999).
Recently, a new potential probiotic strain, P. pento-
saceus OZF, has been isolated from human breast milk
(Osmanagaoglu et al. 2010). The strain OZF has been
shown to tolerate low pH, pepsin, bile acid and pancreatic
fluid under in vitro conditions, to bind human Caco-2 cells
and to exert inhibitory activity against a wide range of bacte-
ria, including some pathogens by producing pediocin AcH/
PA-1 (Osmanagaoglu et al. 2010, 2011). Since the strain was
shown to fulfill in vitro probiotic selection criteria, the study
was extended one step further, and this article presents results
of some in vivo pre-selective studies on promising probiotic P.
pentosaceus OZF, such as the survival in the GIT of mice and
its effects on the immune system modulation.
Materials and methods
In vivo survival of Pediococcus pentosaceus OZF
during passage through GIT of mice
Maintenance of animals Seven-week old female BALB/c
mice weighing 20–22 g were purchased from Gazi Univer-
sity Animal Reproduction and Animal Research Center
(GUDAM) and were housed in stainless-steel cages with a
12 h light/dark cycle under specific pathogen-free controlled
environmental conditions (temperature 22±1 °C, humidity
55±5 °C). Mice were fed with an unlimited commercial
rodent diet (Harlan, Barcelona, Spain) and water ad libitum
during the experimental protocol. The protocol was carried
out according to the guidelines of the Helsinki declaration
and was approved by the Local Ethics Committee on Ani-
mal Experiments of the Gazi University, Ankara, Turkey
(G.U.E.T., Protocol No: 07/0029).
Preparation of bacterial suspension and administration to
mice Pediococcus pentosaceus OZF was grown in tryptone-
glucose-yeast extract (TGE) broth at 37 °C for 18 h. Cells
were removed by centrifugation at 3,000 g for 10 min,
washed twice with physiological saline solution and resus-
pended in the same solution to a final concentration of 108
CFU per 200 μL. Mice in the experimental group (n=7)
received a daily dose of 108CFU of bacterial suspension,
while the control group (n=7) received 200 μL of physio-
logical saline solution by intragastric gavage. Sera, spleen
cells and peritoneal exudate cells (PECs) obtained from
mice fed 30 days with P. pentosaceus OZF were used for
detection of in vivo immunomodulatory capacity of the
strain, while feces of mice fed 5 days with OZF were used
in viability (survival ability in GIT) studies.
Recovery of Pediococcus pentosaceus OZF from feces The
mice were fed with bacterial suspension regulary for 5 days.
The survival ability of P. pentosaceus OZF through the GIT
was investigated every day for 5 days, by analyzing the
recovery of the strain in fecal samples as bacteriocin-
producing colonies. At the end of 5 days, the feeding trial
was stopped, but fecal samples were collected for 5 addition-
al days to check the colonization ability of the strain, and
subjected to the same analysis. For this aim, daily collected
fecal samples were pooled, resuspended in physiological
saline solution (100 mg mL−1) and mechanically homoge-
nized. Dilutions were plated onto Pediococci Selective Me-
dium (PSM) agar and incubated at 37 °C for 24 h before
enumeration (Simpson et al. 2006). To verify existence of P.
pentosaceus OZF in feces, bacteriocin assay and PCR-based
methods were applied before and after administration.
For bacteriocin assay, following pour plating, the plates
containing ∼50 to 100 colonies were overlaid with TSB
(Tyriptic soy broth) soft agar seeded with Listeria monocy-
togenes ATCC 7644 as an indicator. Plates were further
incubated overnight at 37 °C and examined for the presence
of an inhibition halo against L. monocytogenes ATCC 7644
(Biswas et al. 1991). The bacteriocin-producing colonies on
PSM medium were counted as CFU mL−1. Approximately
50 colonies passed through GITwere randomly picked from
plates, observed microscopically, Gram-stained and then
subjected to API kit for identification. Identification was
confirmed by 16S rDNA sequencing using specific univer-
sal primers (Edwards et al. 1989; Osborne et al. 2005) as
previously discussed (Osmanagaoglu et al. 2011). Amplified
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PCR fragments were purified by PCR purification kit (Prom-
ega, Agarose Gel DNA Extraction Kit) and sequenced by
REFGEN Biotechnology (METU Technocity, Ankara, Tur-
key). Basic local alignment search tool (BLAST) was used to
compare the sequences with the one deposited for P. pentosa-
ceus OZF (accession number 1337739, 706 bp) in National
Centre for Biotechnology Information (NCBI) (http://
www.ncbi.nlm.nih.gov.tr/BLAST).
For P. pentosaceus OZF detection from feces by using
PCR based methods, multiplex PCR was carried out first.
DNA templates for PCR reactions were prepared from bac-
teriocin producing colonies. One colony was resuspended in
50 μL of sterilized TE (10 mM Tris–HCl, 1 mM EDTA pH
7.5) buffer and boiled for 10 min. Supernatant containing
released DNA was directly used as template in PCR ampli-
fication. Target specific genes for pediococci, P. pentosa-
ceus and pediocin AcH/PA-1 were amplified by using the
method proposed by Suwanjinda et al. (2009). To determine
whether or not the original OZF strain and the strains obtained
in the feces following oral administrationwere the same strain,
the recovered strains were further typed by RAPD profile.
DNAwas extracted by using Promega DNA isolation kit, and
PCR was carried out with using different RAPD primers
[OPO-09 (5 ′ TCCCACGCAA 3 ′ ) , OPF -14 (5 ′
TGCTGCAGGT 3′), and OPA-07 (5′ GAAACGGGTG 3′)].
Immunomodulatory function of Pediococcus pentosaceus
OZF
Culture medium, cytokines, antibodies and reagents All cell
culture media components were obtained from Hyclone
(USA). Cytokine ELISA assay reagents, recombinant
mouse IL-6, IL-12 and IFN-γ, and their monoclonal and
biotinylated antibodies were obtained from Thermo, Pierce
Endogen and BD Biosiences, respectively. Streptavidin-
alkaline phosphatase (SA-AKP) and p-nitrophenyl phos-
phate disodium salt substrate (PNPP) were purchased from
Thermo. Lipopolysaccharide (LPS) and peptidoglycan
(PGN), isolated from Escherichia coli, was obtained from
Sigma. Immunsuppressive CpG oligodeoxynucleotide
(ODN) K-type; K23 (12mer) and control ODN were chem-
ically synthesized by Alpha DNA (Montreal, Canada).
Cell culture and stimulation assay BALB/c mice involved
in control and experimental groups were used after a 30 day
daily feeding period. Mice were euthanized by cervical
dislocation. Blood, spleen cells and PECs were aseptically
extracted and used for further analysis. Sera were obtained
by centrifugation (1,000 g for 5 min at room temperature,
RT) and stored at −20 °C until ELISA (Enzyme-linked
immunosorbent assay) was carried out. Unstimulated spleen
cells (4 millions of cells in 200 μL), PECs (200.000 cells in
200 μL) and serum samples of mice were used for in vivo
detection of immunomodulatory function in strain OZF. In
addition, stimulated forms were used to understand the
differentation of immunostimulatory effect between the con-
trol and experimental group. For stimulation assay, spleen
cells and PECs in 96 well plates were stimulated with three
increasing concentrations of ss DNA (0.08, 0.8 and 8 μg in
200 μL) and heat killed cells of P. pentosaceus OZF (107 to
102CFU mL−1). DNA of P. pentosaceus OZF was extracted
with Promega Wizard DNA purification kit. To avoid stim-
ulatory effects due to contamination of bacterial proteins or
LPSs, DNA preparations used in the experiments had purity
values higher than 1.8 (OD260/280). Single-stranded DNA
was prepared by heat denaturing of double-stranded DNA at
95 °C for 5 min, followed by cooling on ice. To obtain heat
killed cells, the remaining culture fluid was heated to 121 °C
for 15 min, and washed three times with PBS (phosphate
buffer saline pH 7.2). For positive controls, LPS (5 μg
mL−1), PGN (5 μgmL−1), CpG-ODN K23 (1 μM) and
CONTROL ODN (1 μM) were used. Stimulations were
performed in duplicate wells for each indicated treatment.
The cells were incubated overnight at 37 °C in a 5 % CO2
incubator and following incubation, collected superna-
tants were stored at −20 °C for further use.
Evaluation of cytokines production by ELISA Unstimulated
and stimulated serum and cells supernatants were immedi-
ately analyzed by ELISA, to measure the IL-6, IL-12 and
IFN-γ concentrations as described in Erikci et al. (2011).
The optical densities of the enzymatic reaction solutions
were read using an automatic ELISA plate reader (Molecu-
lar Devices, SoftmaxPro Software V5) at 405nm until re-
combinant standards (with the starting concentrations of
4,000 ng mL−1 for IL-6, 100 ng mL−1 for IL-12 and
1,000 ng mL−1 for IFN-γ) reached a four parameter sat-
uration. All ELISA assays were performed in duplicate for
each group.
Statistical analysis
A student’s t test was used to evaluate the statistical signifi-
cances (p<0.05) of the differences in cytokine production of
mice before and after exposure to tested bacterium. Values
of p<0.05 were considered significant.
Results and discussion
In vivo survival of Pediococcus pentosaceus OZF
during passage through GIT of mice
From a safety as well as a functional point of view, it is
essential to determine if a strain survives in the GIT. In the
present study, following oral administration to mice, the
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ability of P. pentosaceus OZF to pass and survive through
the mouse GIT was investigated by analyzing the recovery
of the strain in fecal samples as bacteriocin-producing col-
onies. Clear inhibition zones characterized as bacteriocin
production against L. monocytogenes ATCC 7644 were
observed in all colonies recovered from fecal samples after
administration with the strain OZF, and it has been sug-
gested that ingested bacteria as probiotics cannot affect the
intestinal environment unless their population reaches a
certain minimum level of between 106 and 108CFU g−1 in
intestinal content (Marteau and Rambaud 1993). According
to PSM counts, no Pediococcus was recorded in feces of
mice belonging to control groups, highlighting the lack of
this genus within the intestinal flora of mice (Data not
shown). Viable cells of P. pentosaceus OZF administered
orally to mice decreased time dependently (Fig. 1). Twelve
hours after the first administration, the strain OZF appeared
at a level of 107 CFU g−1 in feces of all mice in the treated
group and at a level of 106to 107CFU g−1 after further 24 h .
The strain OZF was detected in three of seven mice at
gradually reduced levels at 48, 72, 96 and 120 h. This
indicates that P. pentosaceus OZF administered to mice
can survive in the stomach and reach the mouse intestine
alive. However, the strain OZF was not detected in any
mouse at 144 h (24 h after the administration had ceased).
Feeding trials with the strain OZF showed that the promis-
ing probiotic strain disappears from the GIT within 1 day
after the feeding was discontinued. This indicates that the
strain could not get through to colonize in the mouse intes-
tine and although it could reach the intestine alive, is elim-
inated from the intestine. This is because the normal
intestinal microbiota provide an excellent resistance against
colonization by introduced bacteria (Wells et al. 1988). On
the other hand, pediococci were not detected in the control
group. However, other studies showed that the number of
probiotic bacteria detected 14 days after the administration
of probiotic strains was lower than on the first day after
administration (Murphy et al. 1999). This observation is
supported by results of a human study completed by Goldin
et al. (1992) where it was demonstrated that 60–80 % of
individuals consuming Lactobacillus rhamnosus GG excret-
ed the bacterium for 3–4 days, but only 33 % of the popu-
lation excreted the bacterium after 7 days. In a similar study,
the probiotic strain could be recovered (with no oral supple-
mentation) from feces up to 3 days after cessation of feed-
ing. Therefore, it appears increasingly likely that daily
administration of the preferred strain is necessary for main-
tenance of high levels of probiotics (Murphy et al. 1999).
By using bacteriocin-producing ability, the survival and
persistence of the administered strain could be monitored after
transit in the GIT of mice. Almost 50 (ten for each day of
administration) randomly selected bacteriocin-producing col-
onies were found in tetrad morphology, Gram-positive and
catalase-negative. Nevertheless, to avoid the risk of mistaking
colonies of Pediococcus spp. grown on PSM agar medium,
multiplex and RAPD PCR were used. PCR was performed on
the colonies grown on PSM agar to detect live bacterial cells
in feces (Fig. 2). Biochemical profiles of five randomly chosen
strains were obtained with API 50CH (bioMerieux) following
the manufacturer’s guidelines and identified as P. pentosa-
ceus. Besides, 16S rRNA sequence analysis allowed us to
identify the five strains as P. pentosaceus, and the obtained
sequences were found to be the same (99 % similarity) that
have already been registered for OZF strain in GenBank
database system under accession number HM051378
(706 bp). Multiplex PCR profiles of 50 randomly selected
colonies from the fecal samples of treated mice group were all
found to be identical to the pattern of administered P. pento-
saceusOZF. Amplification of template DNA obtained from P.
pentosaceus OZF before and after administration, using spe-




















Fig. 1 Survival and time dependent changes in the fecal populations
of P. pentosaceus OZF after oral administration to mice
Fig. 2 Molecular identification of Pediococcus pentosaceus OZF in
mouse feces by multiplex-PCR. Lane M, 100 bp DNA ladder (Gen-
eRulerTM 100 bp DNA Ladder Plus, Fermentas); Lane 1, negative
PCR control (no template DNA); Lane 2, P. pentosaceus OZF used for
oral administration to mice as positive control; Lane 3–7, multiplex-
PCR products derived from colonies on PSM agar after oral adminis-
tration of P. pentosaceus OZF at 1, 2, 3, 4 and 5 days respectively
1314 Ann Microbiol (2013) 63:1311–1318
fragments with molecular weights of 500 and 278 bp specific
for P. pentosaceus, and a 332 bp DNA fragment for pediocin
AcH/PA-1 (Fig. 2). RAPD-PCR for the same randomly se-
lected colonies generated reproducible patterns identical to
fingerprint obtained for P. pentosaceus OZF (Fig. 3). There-
fore, the one representing each day was choosen randomly
and its band profiles are shown in Fig. 3. Multiplex PCR was
found to be an easy, fast, reliable and reproducible method,
and can be used as an alternative for verification of
bacteriocin-producing pediococci strains. RAPD-PCR was
also found as a rapid and reliable molecular technique to
generate DNA fingerprints for each strain, and to distinguish
the ingested strain from the potentially thousands of other
bacterial strains that make up the gastrointestinal ecosystem.
Immunomodulatory function of Pediococcus pentosaceus
OZF
Some LAB strains may be able to activate the immune
system cells (Christensen et al. 2002; Medina et al. 2007;
Vizoso Pinto et al. 2007, 2009). Inducing or enhancing the
cytokine production could be a major mechanism for pro-
biotic bacteria to exert immunomodulating activities (Marin
et al. 1997). This would open up a promising use of P.
pentosaceus OZF as an immunomodulator. Our study was
performed in two stages, in vivo and in vitro. The analysis
of the cytokines profiles revealed that the most remarkable
effect was an increase in the IL-6 (Fig. 4), an important
mediator both in humoral and cellular host defense. IL-6
plays an important role in host immune mechanism by
regulating immune response and acute-phase reactions
(Morita et al. 2002). In control group, IL-6 was not detected
in sera, while a statistically significant increase was detected
in mice regularly fed with bacterial suspension (89.15±
7.89 ng mL−1, p<0.001). On the other hand, no significant
difference was recorded in IL-12 production between groups
(control: 3.96±1.58 ng mL−1; experimental: 4,82±1.72 ng
mL−1). Besides, the resulting amount of IFN gamma level
was below the detection level of the method in cell super-
natants including serum (Fig. 4). The increase in the pro-
duction of IL-6, as a result of regular feeding with P.
pentosaceus OZF, may create an advantage for defense of
infections encountered in any way (Van Enckevort et al.
1999). Despite growing evidence for immunomodulatory
capability of LAB, especially human milk-derived species,
there is still little information regarding their mode of action.
Several similar studies have reported the in vitro and in vivo
cytokine response patterns of co-culturing cells of the innate
immune defense system with different probiotic LAB for
understanding their health protection mechanism. Our
results are in agreement with the results obtained by Gill
(1998); Morita et al. (2002); Kimura et al. (2006); Foligne et
al. (2010); Perez-Cano et al. (2010) and Zhu et al. (2011).
Intestinal epithelial cells from conventional mice were
reported to produce IL-6 in response to the challenge in
Fig. 3 Molecular typing of
Pediococcus pentosaceus OZF
in mouse feces by RAPD PCR.
Lane M, 100 bp DNA ladder
(GeneRulerTM 100 bp DNA
Ladder Plus, Fermentas; Marker
bp, ruler was given at Fig. 2);
Lane 1, negative PCR control
(no template DNA); Lane 2, P.
pentosaceus OZF used for oral
administration to mice as
positive control; Lane 3–7,
RAPD PCR profiles derived
from colonies on PSM agar after
oral administration of P.
pentosaceusOZF at 1, 2, 3, 4 and
5 day respectively. Primers used
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Fig. 4 IL-6, IL-12 and IFN-γ production in serum samples of BALB/c
mice involved in control and experimental group after 30 days daily
feeding period (*significantly difference: p<0.001)
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vitro with certain LAB strains that had also demonstrated in
vivo immunomodulating capacity (Vinderola et al. 2005).
Two P. pentosaceus strains isolated from traditional vegetable
pickles were shown to have a high capacity to survive in the
GIT, and have in vitro immunomodulatory and allergy inhibi-
tion effects (Jonganurakkun et al. 2008). In contrast, anotherP.
pentosaceus strain, used as preservative to prevent farmer’s
lung pneumonitis, was shown to induce an inflammatory
response in mice in the study of Duchaine et al. (1996).
In order to find out whether or not P. pentosaceus OZF
exhibit in vitro immunostimulating capacity, ssDNA and
heat killed cells of the strain were used, since it is known
that cellular components of LAB such as peptidoglycans,
lipoteichoic acids, cell surface protein, exopolysaccharide
and DNA CpG motifs, as well as live bacteria and inacti-
vated bacteria, may present a capacity for immune system
stimulation (Lebeer et al. 2008; Ng et al. 2009). In both
experimental and control groups, stimulation studies were
carried out by use of both spleen cells and PECs. Following
stimulation, the release of IL-6 and IL-12 was not detected
in spleen cells. In PECs, when we look at the results from
the perspective of IL-6 production after stimulation, the
control group was found to react more than experimen-
tal group to high dosage of heat killed cells of the
strain OZF (p<0.01). However, when the concentration
of heat killed cells was decreased (104CFU mL−1 and
lower titrations), IL-6 production was found to be higher in
the experimental group than in the control group (p<0.05).
When the results of heat killed bacteria stimulation are
evaluated in terms of IL-12 and IFN gamma secretion,
no significant difference was recorded between the groups
(data not shown).
Although studies are limited in this regard, available refer-
ences reported that DNA of LAB have immunostimulatory
properties (Lammers et al. 2003; Iliev et al. 2005; Li et al.
2005; Medina et al. 2007; Ghadimi et al. 2008; Satokari et al.
2009; Menard et al. 2010). The present study showed that
ssDNA of P. pentosaceus OZF induced the secretion of IL-6
and IL-12, but this was not found to be significantly different
when compared to each group (data not shown). IFN-γ was
not detected after stimulation with ssDNA, which could be
related to the use of low dosages of ssDNA.
In conclusion, P. pentosaceus OZF strain proved to be
able to pass live through the GIT after oral administration to
mice and to stimulate an immune response. To the authors'
knowledge, this is the first article dealing with the effects of
a Pediococcus strain, isolated from human breast milk, on
cytokines activation. The comparison of the stimulant effect
of heat killed cells and ssDNA after co-culture with spleen
cells and PECs is also novel. On the other hand, further
studies are necessary to better assess the fulfill breadth of the
immunomodulatory capability of our strain in the gut envi-
ronment, and to understand its cellular or humoral immune
effect by measuring the inductive activity of IgA, IgG and
IgM in case of usage as a oral vaccine carrier.
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